IGHM antibody (AA 45-178)

Catalog No. ABIN7156089

Product Details anti-IGHM Antibody

Target: IGHM (Immunoglobulin Heavy Constant mu (IGHM))

Binding Specificity: AA 45-178

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This IGHM antibody is un-conjugated

Application: Immunohistochemistry (IHC), Western Blotting (WB), ELISA

Cross-Reactivity: Human

Purification: >95%, Protein G purified

Immunogen: Recombinant Human Immunoglobulin heavy constant mu protein (45-178AA)

Isotype: IgG

Application Details

Application Notes: Recommended dilution: WB:1:500-1:5000, IHC:1:500-1:1000,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for IGHM

Target: IGHM (Immunoglobulin Heavy Constant mu (IGHM))

Alternative Name: IGHM (IGHM Products)

Synonyms: AI326478 antibody, Igh-6 antibody, Igh-M antibody, Igh6 antibody, Igm antibody, muH antibody, ighm1 antibody, wu:fj14a08 antibody, zgc:101769 antibody, AGM1 antibody, MU antibody, VH antibody, immunoglobulin heavy constant mu antibody, Ighm antibody, ighm antibody, IGHM antibody

Background:

Background: Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268). IgM antibodies play an important role in primary defense mechanisms. They have been shown to be involved in early recognition of external invaders like bacteria and viruses, cellular waste and modified self, as well as in recognition and elimination of precancerous and cancerous lesions. The membrane-bound form is found in the majority of normal B-cells alongside with IgD. Membrane-bound IgM induces the phosphorylation of CD79A and CD79B by the Src family of protein tyrosine kinases. It may cause death of cells by apoptosis. It is also found in soluble form, which represents about 30 % of the total serum immunoglobulins where it is found almost exclusively as a homopentamer. After the antigen binds to the B-cell receptor, the secreted form is secreted in large amounts (PubMed:3137579, PubMed:16895553).

Aliases: IGHMImmunoglobulin heavy constant mu antibody, Ig mu chain C region antibody, Ig mu chain C region BOT antibody, Ig mu chain C region GAL antibody, Ig mu chain C region OU antibody

UniProt: P01871